imatinib mesylate has been researched along with Secondary Hyperparathyroidism in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Browett, P; Callon, K; Ebeling, P; Gamble, G; Grey, A; Horne, A; O'Sullivan, S; Porteous, F; Wattie, D | 1 |
| Han, SB; Jung, WK; Kim, SJ; Lee, SH; Park, SW; Park, SY; Yang, KH | 1 |
| Amet, Y; Berthou, C; Dalbies, F; Eveillard, JR; Grall, P; Guillerm, G; Ianotto, JC; Tempescul, A | 1 |
| Jönsson, S; Mellström, D; Olsson, B; Standal, T; Wadenvik, H | 1 |
| Browett, P; Grey, A; O'Sullivan, S; Reid, IR | 1 |
2 trial(s) available for imatinib mesylate and Secondary Hyperparathyroidism
| Article | Year |
|---|---|
Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Remodeling; Fanconi Syndrome; Female; Humans; Hyperparathyroidism, Secondary; Hypophosphatemia; Imatinib Mesylate; Kidney Tubules, Proximal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Biological; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Renal Aminoacidurias | 2012 |
Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents; Benzamides; Biomarkers; Bone Density; Calcium; Collagen Type I; Female; Humans; Hyperparathyroidism, Secondary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnesium; Male; Menopause; Middle Aged; Osteocalcin; Parathyroid Hormone; Peptides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Smoking | 2012 |
3 other study(ies) available for imatinib mesylate and Secondary Hyperparathyroidism
| Article | Year |
|---|---|
Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib.
Topics: Aged; Benzamides; Bone and Bones; Bone Density; Calcitriol; Calcium; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Imatinib Mesylate; Male; Middle Aged; Parathyroid Hormone; Phosphates; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Serum Albumin; Vitamin D | 2009 |
Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Bone and Bones; Bone Remodeling; Female; Femoral Fractures; Humans; Hyperparathyroidism, Secondary; Hypophosphatemia; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Pyrimidines; Radiography | 2010 |
Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism.
Topics: Adult; Benzamides; Biomarkers; Bone Remodeling; Calcium; Female; Fusion Proteins, bcr-abl; Humans; Hyperparathyroidism, Secondary; Hypophosphatemia; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Pyrimidines | 2006 |